Human eosinophils are known to lose Ia antigen expression as they mature, and, accordingly, eosinophils obtained from the blood of five eosinophilic donors and three of four normal donors failed to display the major histocompatibility complex class II antigen HLA-DR, as determined by flow cytometry. However, when eosinophils from these nine donors were maintained in culture with recombinant human granulocyte-macrophage colony-stimulating factor and murine 3T3 fibroblasts, HLA-DR consistently developed on the eosinophils. By days 4-6 of culture, 24-97% ofeosinophils were HLA-DR+, and the eosinophils remained morphologically mature. In contrast, another class H antigen, HLA-DQ, was not detectable by flow cytometry on eosinophils from eight of nine donors. Cultured eosinophils were able to synthesize Culture of Eosinophils. Enriched eosinophils (1.5 x 106) were cultured in 3 ml of RPMI 1640 medium containing 10%6 (vol/vol) fetal calf serum and 150 units (=50 pM) of rhGM-CSF (expressed in yeast and purified to homogeneity; Genzyme) with an adherent monolayer of Swiss 3T3 fibroblasts (American Type Culture Collection) at 370C (5% C02/95% air) as described (7); 1.5 ml of culture medium was exchanged with fresh RPMI 1640/10% fetal calf serum/rhGM-CSF on days 2, 5, and 7. Nonadherent cells were collected on the indicated days; prior to flow cytometry, cell viability (>90%) was assessed with trypan blue and cell morphology was assessed by staining with phloxine-methylene blue and fast green-neutral red stains for eosinophils (8).
onine into immunoprecipitable HLA-DR heavy and light chains. These findings show that mature eosinophils can synthesize and express HLA-DR and provide a means whereby eosinophils may interact with CD4' lymphocytes.
Although eosinophils are notable participants in immunologic responses during allergic and helminthic parasitic diseases, a cooperative mechanism for eosinophil stimulation of lymphocytes has not been defined. Class II major histocompatibility complex (MHC) genes encode proteins that can be expressed on antigen-processing cells, such as macrophages, dendritic cells, and B lymphocytes, as well as on activated T lymphocytes (reviewed in refs. 1 and 2). The class II MHC protein HLA-DR mediates the MHC-restricted interactions of antigen-presenting cells with CD4+ lymphocytes (1) (2) (3) . Although class II proteins are present on early granulocyte precursor cells in the bone marrow, both human eosinophils (4) and neutrophils (5) , with differentiation and maturation, become uniformly HLA-DR-. We have found that HLA-DR-peripheral blood eosinophils synthesize and express HLA-DR while maintained in culture with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and murine fibroblasts. The inducibility of HLA-DR on eosinophils could provide a mechanism for eosinophils to interact with, and potentially present antigen to, CD4+ lymphocytes. (American Type Culture Collection) at 370C (5% C02/95% air) as described (7); 1.5 ml of culture medium was exchanged with fresh RPMI 1640/10% fetal calf serum/rhGM-CSF on days 2, 5, and 7. Nonadherent cells were collected on the indicated days; prior to flow cytometry, cell viability (>90%) was assessed with trypan blue and cell morphology was assessed by staining with phloxine-methylene blue and fast green-neutral red stains for eosinophils (8 by fluorography of gels exposed for 14 days at room temperature with Kodak X-Omat film. RESULTS Eosinophils, obtained from nine donors (five with and four without blood eosinophilia) and maintained in culture with adherent murine fibroblasts and rhGM-CSF, were shown by flow cytometry to express HLA-DR (Fig. 1) . Peripheral blood eosinophils purified from eight of these nine donors were HLA-DR-prior to culture. As evaluated in 14 studies, after 4-6 days in culture, eosinophils from each donor became HLA-DR' (24-97%) ( Table 1) . Eosinophil cellsurface expression of HLA-DR was evident by day 2 of culture and was maximal by days 3-7 (Fig. 2) . In contrast, another class II MHC antigen, HLA-DQ-also not detectable on eosinophils before culture, was expressed on cultured eosinophils from only one donor (Table 1) .
MATERIALS AND METHODS
As assessed on day 5 of culture, the average mean channel fluorescence above background for the HLA-DR+ eosinophils was 45.9 (range, 28.6-65.0). For the eight cultures in which >75% of eosinophils were HLA-DR+, eosinophil staining showed a unimodal distribution (e.g., Fig. 1 The identity of the cultured HLA-DR' cells as eosinophils was ascertained by light microscopy and flow cytometry. By day 5 of culture, >95% of the nonadherent cells were eosinophils. These cells had the morphologic and tinctorial features of eosinophils by Wright-Giemsa, neutral red-fast green (8) and phloxine-methylene blue (8) staining. Specific staining of eosinophil cytoplasmic granules was demonstrable with fast green and phloxine stains. Furthermore, the cultured eosinophils were morphologically mature, with condensed, segmented, primarily bi-lobed nuclei as reported (7) . Contaminating neutrophils, representing 6-35% of leukocytes at the start of cultures (Table 1) , do not survive under these culture conditions (7) and were not detectable by days 4-6 by cytologic staining or by flow cytometry with anti-CD16 monoclonal antibody. In addition, the absence of other cells known to express HLA-DR was corroborated by stain- ing cultured cells with monoclonal antibodies for monocytes and T cells ( Table 1) .
The specificity of HLA-DR expression on cultured eosinophils was confirmed with a second HLA-DR-specific monoclonal antibody, LB3.1, which immunoprecipitates both chains of HLA-DR (10) . From extracts of cultured eosinophils labeled with [35S]methionine in the absence of fibroblasts, this monoclonal antibody precipitated proteins with molecular masses of 27.5 and 32.4 kDa (Fig. 3) , consistent with the light and heavy chains of HLA-DR (10). The same findings were obtained with eosinophils from donors with and without eosinophilia. DISCUSSION Ia antigen (4) and specifically HLA-DR (12) are expressed on eosinophil colony-forming cells. Since class II MHC antigens are absent from more mature eosinophils, the expression of HLA-DR on granulocytes has been taken as a differentiation marker, with expression limited to the earliest stages of development (4) . Thus, the effect of culturing mature human HLA-DR-eosinophils with rhGM-CSF and fibroblasts was notable for the de novo expression ofan MHC class II antigen on a type of leukocyte not previously recognized to express such antigens. HLA-DR was absent on mature eosinophils circulating in the blood of all but one of the normal and eosinophilic donors but was expressed by these mature eosinophils maintained in culture with rhGM-CSF. Further, the incorporation of [35S]methionine into immunoprecipitable HLA-DR heavy and light chains indicated that there was new synthesis of HLA-DR by eosinophils and not simply its mobilization from an intracellular pool for cell-surface expression.
GM-CSF, which can be produced by T lymphocytes, monocytes, fibroblasts, and endothelial cells (13) (14) (15) , has been recognized to stimulate functions of mature eosinophils (16) , including antibody-dependent cytotoxicity (17, 18) , synthesis of leukotriene C4 in response to calcium ionophore stimulation (17) , and cell-surface expression of antigens granulocyte function antigen 1 (GFA-1) and Mol (18 longed eosinophil survival in culture (18) , and its presence was required to maintain the viability of eosinophils cultured with 3T3 fibroblasts (7) . Utilizing the coculture system with 3T3 fibroblasts and GM-CSF, we have shown that eosinophils during in vitro culture can express HLA-DR. Because both fibroblasts and GM-CSF were needed to maintain eosinophil viability in culture as noted before (7), the specific roles of GM-CSF and fibroblasts in eliciting HLA-DR expression by eosinophils could not be determined. The 50 pM concentration of rhGM-CSF used would be in accordance with the dissociation constant of eosinophil GM-CSF receptors and within the range of GM-CSF concentrations eliciting physiological responses (19) . On other cell types, GM-CSF has augmented MHC class II Ta antigen expression on adherent murine spleen cells (20) , enhanced the accessory cell function of murine spleen and epidermal Langerhans cells (20, 21) , and increased the Ia expression and Ia-related functions of murine macrophages (22) .
Cultured eosinophils consistently expressed HLA-DR but not HLA-DQ. A similar predominance of HLA-DR expression has been noted on other cell types including monocytes (23) , Kupffer cells (24) , and synovial lining cells (25) . Differential regulation of expression of these two MHC class II proteins in HL-60 myelomonocytic cells has been noted (26) , but the mechanism and significance of the predominant HLA-DR expression by eosinophils, as well as by other cell types, are not defined. The mean fluorescence intensity of HLA-DR expression on eosinophils was less than that on y interferon-stimulated monocytes, but for eosinophils from all cultures, there was considerable overlap in fluorescent HLA-DR staining between the HLA-DR' eosinophils and the activated monocytes. Other cytokines, alone or in concert, may elicit greater expression of HLA-DR on eosinophils.
The circulating blood eosinophils from eosinophilic donors included eosinophils of normal and diminished (hypodense) density. Donor 1, for instance, on two separate occasions had >95% hypodense eosinophils as assessed with metrizamide density gradients (7) (data not shown). The absence of HLA-DR on the cells from eosinophilic donors would suggest that HLA-DR expression is not an early marker for the apparently activated hypodense eosinophils (7, 27) , although HLA-DR expression might develop after these cells leave the circulation for more prolonged residence in tissues (28) . Quantitatively >99% of eosinophils are present in tissues (28) where eosinophil function is subject to stimulatory cytokines (16) . In response to parasitic infections, eosinophils can serve as helminthotoxic effector cells (29) , and in allergic diseases eosinophils are a source of immunopathogenic mediators (27) . Our 
